Product news from 09/09 News Brief

Share this article:

Takeda Pharmaceuticals North America announced that the FDA has approved the New Drug Application for ACTOplus Met for the treatment of type 2 diabetes.

Cephalon has entered into an agreement with McNeil Consumer & Specialty Pharmaceuticals to co-promote Attenace (modafinil) Tablets. Attenace is Cephalon's proprietary dosage form of modafinil, which is awaiting FDA approval for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. 

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.